Intranasal Oxytocin Attenuates Cognitive Impairment, β-Amyloid Burden and Tau Deposition in Female Rats with Alzheimer's Disease: Interplay of ERK1/2/GSK3β/Caspase-3

Neurochem Res. 2022 Aug;47(8):2345-2356. doi: 10.1007/s11064-022-03624-x. Epub 2022 May 20.

Abstract

Oxytocin is a neuropeptide hormone that plays an important role in social bonding and behavior. Recent studies indicate that oxytocin could be involved in the regulation of neurological disorders. However, its role in modulating cognition in Alzheimer's disease (AD) has never been explored. Hence, the present study aims to investigate the potential of chronic intranasal oxytocin in halting memory impairment & AD pathology in aluminum chloride-induced AD in female rats. Morris water maze was used to assess cognitive dysfunction in two-time points throughout the treatment period. In addition, neuroprotective effects of oxytocin were examined by assessing hippocampal acetylcholinesterase activity, β-amyloid 1-42 protein, and Tau levels. In addition, ERK1/2, GSK3β, and caspase-3 levels were assessed as chief neurobiochemical mediators in AD. Hippocampi histopathological changes were also evaluated. These findings were compared to the standard drug galantamine alone and combined with oxytocin. Results showed that oxytocin restored cognitive functions and improved animals' behavior in the Morris test. This was accompanied by a significant decline in acetylcholinesterase activity, 1-42 β-amyloid and Tau proteins levels. Hippocampal ERK1/2 and GSK3β were also reduced, exceeding galantamine effects, thus attenuating AD pathological hallmarks formation. Determination of caspase-3 revealed low cytoplasmic positivity, indicating the ceasing of neuronal death. Histopathological examination confirmed these findings, showing restored hippocampal cells structure. Combined galantamine and oxytocin treatment showed even better biochemical and histopathological profiles. It can be thus concluded that oxytocin possesses promising neuroprotective potential in AD mediated via restoring cognition and suppressing β-amyloid, Tau accumulation, and neuronal death.

Keywords: Alzheimer; Cognitive impairment; Oxytocin; Tau; β-Amyloid.

MeSH terms

  • Acetylcholinesterase / metabolism
  • Alzheimer Disease* / chemically induced
  • Alzheimer Disease* / drug therapy
  • Alzheimer Disease* / metabolism
  • Amyloid beta-Peptides / metabolism
  • Animals
  • Caspase 3 / metabolism
  • Cognitive Dysfunction* / drug therapy
  • Disease Models, Animal
  • Female
  • Galantamine / pharmacology
  • Galantamine / therapeutic use
  • Glycogen Synthase Kinase 3 beta / metabolism
  • MAP Kinase Signaling System
  • Oxytocin* / pharmacology
  • Oxytocin* / therapeutic use
  • Rats
  • tau Proteins / metabolism

Substances

  • Amyloid beta-Peptides
  • tau Proteins
  • Galantamine
  • Oxytocin
  • Glycogen Synthase Kinase 3 beta
  • Acetylcholinesterase
  • Caspase 3